Nasus Pharma is trading at $3.79 (+5.57%) after announcing the first patient was enrolled and dosed in its Phase 1 NS003 study. - Announced September 29, 2026, NS003 is an intranasal ondansetron formulation for chemotherapy-related and post-operative nausea and vomiting. - The study will assess its pharmacokinetic and safety profile in humans for the first time; topline data are expected before year-end. - This same-day clinical milestone is a company-specific catalyst; supplied market context indicates no comparable broad-market move.